BioLogicB is a consulting firm headed by Barry Buckland based in the New York area. Barry Buckland is an experienced International expert for the Development of Biologic products with a special focus on vaccines and Therapeutic proteins. Barry has received numerous awards recognizing his contributions throughout his career and is a member of the prestigious USA National Academy of Engineering (NAE).
About
BioLogicB, LLC. Barry Buckland consults in all areas of Bioprocess R&D including the development and commercialization of Therapeutic Proteins , Natural Products, Cell Therapy and Vaccine products.
Barry Buckland by Lisa Berg
Barry C. Buckland, PhD
CEO, BioLogicB, LLC
Telephone: 1-631-803-8356
E-mail: buckland@BioLogicB.com
P.O.BOX 559
Bellport, NY 11713 USA
Top of the page
Awards
- The Pharmaceutical Research and Manufacturers of America (PhRMA), Discoverers Award for the development of a vaccine effective against HPV and Cervical Cancer (GARDASIL), with Eliav Barr and Kathrin Jansen in 2009.
- American Institute of Chemical Engineering (AIChE), named as one of the "One Hundred Chemical Engineers of the Modern Era" as part of the AIChE Centennial celebration in Philadelphia in 2008.
- American Chemical Society (ACS), Marvin Johnson Award for Lifetime Achievement in Biotechnology in 2008
- Merck & Co, Inc, Board of Directors Award for leading process development for licensure of four new vaccines in 2007.
- UK Institute of Chemical Engineering, Donald Medal for outstanding contributions to Biotechnology in 2002.
- University College London, elected Fellow in 1998.
- National Academy of Engineering, elected as member in 1997.
Previous Position
Responsible for building and leading a world class Bioprocess R&D organization at the Merck Research Laboratories. During this period, mostly as Vice President, Barry was involved in the development, transfer to manufacturing, licensure and launch for many key products including :
- MEVACOR® (A natural product used for cholesterol lowering)
- ZOCOR® (Derived from Mevacaor)
- IVOMEC® (Anti parasitic drug for both animals and humans)
- CANCIDAS® (A natural product with excellent anti fungal activity)
- RECOMBIVAX HB® (Vaccine against Hepatitis B)
- VAQTA® (Hepatitis A Vaccine)
- VARIVAX® (Chicken pox vaccine)
- COMVAX® (Combination pediatric vaccine)
- ROTATEQ® (Rotavirus vaccine for infant diarrhea)
- ZOSTAVAX® (Vaccine against shingles)
- GARDASIL® (Vaccine against Human Papillomovirus HPV)
Top of the page
Current Position
Since May, 2009
- CEO, BiologicB LLC (Consulting company working with Biotechnology and Vaccine products).
- Chair, Board of Directors, Engineering Conferences International (ECI) (A not for profit organization which brings prestigious International conferences to the engineering community).
- Scientific Advisory Committee, IAVI.
- Visiting Professor, Dept of Biochemical Engineering , University College London.
- Executive Director (NIIMBL) The National Institute for Innovation in Manufacturing Biopharmaceuticals..
- Senior Advisor, Protein Sciences.
Areas of Expertise
Bioprocess R&D; Product Development and Commercialization for Vaccines, Therapeutic Proteins, and Cellular Therapies.
Academic Background
- PhD in Biochemical Engineering at University College London, in 1974.
- Over 70 publications in Peer reviewed journals.
- Chaired two ECI International Conferences on Cell Culture (Cell Cuture Engeneering IV and V).
- Co-Chaired the first three ECI International Conferences on Metabolic Engineering.
- Co-Chaired the first three ECI International Conferences on Vaccine Technology.
- Visiting Professor at University College London since 1995.
- VRecent Invited lectures at MIT, Stanford University, UCL, Keck Institute, University of California (Santa Barbara) and Kansas University (2015 and 2016)
- CoChair the first ECI Conference on Microbial Engineering